ZENECA ACCOLATE REDUCES BETA-AGONIST USE BY 22% IN PHASE III TRIAL, SHOWS EFFICACY SIMILAR TO CROMOLYN SODIUM; SEROQUEL PIVOTAL TRIALS FINISHING IN 1995
Executive Summary
Zeneca's leukotriene-receptor antagonist Accolate (zafirlukast) is associated with improvements in daytime asthma symptoms and reductions in nighttime awakenings, according to two Phase III studies presented at the American Academy of Allergy & Immunology annual meeting held Feb. 24-March 1 in New York City.